Biosketch MSGF

Bassem Yamout


Dr. Yamout is currently Professor of Clinical Neurology at the American University of Beirut Medical Center. He graduated from medical school at AUB in 1984, received his training in neurology at the University of Cincinnati-Ohio followed by a fellowship at the Montreal Neurological Institute-McGill University, and joined the faculty of the American University of Beirut in 1988. He is currently head of clinical research at the Multiple Sclerosis Center, president of MENACTRIMS, member of the MSIF Scientific Advisory Board, and fellow of the American Academy of Neurology.

Dr Yamout is one of the leading experts on multiple sclerosis in the Middle East with recent research on epidemiology of the disease in the region, quality of life of patients in the Middle East, and novel therapies such as stem cell transplantation and venous stenosis. In addition he is currently the principal investigator on several ongoing international multiple sclerosis research trials. Dr Yamout has authored many research and review papers and is currently Chief Editor of the MS newsletter “MS today”, and on the editorial board of “Multiple Sclerosis and Related Disorders”, “Journal of Multiple Sclerosis” and “Pediatric Neurology”.

Boyko Alexey

Alexei Boyko gained his MD and PhD from the Russian State Medical University, Moscow and has been Professor of the Department of Neurology and Neurosurgery at this university since 1997. He was the Chief Neurologist of the Department of Health Care of the Government of Moscow in 2001-2015, Director of the Moscow Multiple Sclerosis Center in 2004-2014 and Director of the MS Clinical and Research Center of Neuroclinic (Ysupov Hospital) since 2015. He was elected as a Honourable Professor of Kazan and Yaroslavl State Medical Universities. Professor Boyko has been a member of the “Oslo International Think-tank on Multiple Sclerosis Epidemiology, Analytical Approaches to Study of the Aetiology” at the Center for Advanced Studies of the Norwegian Academy of Science and Letters in 1994-1995, and worked at UBC MS Center in 1998 (Vancouver, Canada). He is also a member of the Presidium of the All-Russian Society of Neurologists, Co-ordinator of the Medical Consulting Boards of Moscow and All-Russian MS Societies, President of RUCTRIMS, member of ECTRIMS Council. Professor Boyko has published 14 books, 12 chapters in books and more than 750 original publications and is a co-editor of three medical journals. The main interest is epidemiology and genetic of MS, immunopathogenesis, clinical trials in MS, he is a member of several Advisory Boards of ongoing and finished clinical trials.


Borg John Joseph

Prof John J Borg is a Director of the Malta Medicines Authority since 2004. Since 2004, Prof Borg has been Malta’s CHMP member at the EMA, but is also the CHMP Member of the Committee of Advanced Therapies.  He is also the Medicines Authority’s Qualified Person for pharmacovigilance and a Visiting Professor for the School of Pharmacy, University of Tor Vergata (Rome).  He has held numerous other academic posts over his career to date such as Docente per il Masters “Scienze Regolatorie del Farmaco” at the University of La Sapienza (Rome) (2015) and  Visiting Senior Lecturer for international Masters Medicines Development course PharmaTrain at the Semmelweis University, (Budapest) (2013-2014). Prof Borg has >12 years responsibility for the approvals/evaluations/inspections of clinical trials phase 1 to IV in Malta with direct hands on experience in policy formulation and medicines regulation (both at European and national level). He has also been appointed rapporteur for the CHMP’s assessment on numerous occasions leading the committee’s scientific evaluation of marketing authorisations.

From 1999 to 2004 Prof Borg worked at the University of Bristol.

Professor Borg holds a degree in Pharmacy with PhD in Pharmacology (Bristol). Prof Borg is an active researcher in regulatory science and has more than 30 scientific publications.

Prof Borg was born in St Julians, Malta and is married with two children.

Brochet Bruno

Bruno BROCHET, MD is Professor of Neurology at University of Bordeaux, France, and Head of the department of Neurology, University Hospital of Bordeaux, France.

He is an MS specialist and he created the MS Clinic of Bordeaux.

He is member of INSERM U 1215 laboratory (Neurocentre Magendie), in Stéphane Oliet’s team, dedicated to research on axons and glia relationships and leads the clinical research group on MS, cognition and imagery. He published mote than 150 papers in peer-reviewed journals.

He is member of several scientific and medical advisory boards on multiple sclerosis (LFSEP, ARSEP, MSIF) and current president of the scientific advisory committee of the Ligue Française contre la Sclérose en plaques (LFSEP) and the Observatoire Français de la SEP (OFSEP)(co-president).

He has been appointed President of the French Neurology Federation in 2015.

Comi Giancarlo


Cohen Jeffrey A., MD

Dr. Cohen is Professor of Medicine (Neurology) in the Cleveland Clinic Lerner College of Medicine.  He received a BA from Connecticut College in 1976 and MD from the University of Chicago School of Medicine in 1980.  He completed a Neurology Residency in 1984 then a Post-doctoral Research Fellowship in Neuroimmunology in 1987, both at the University of Pennsylvania.  Dr. Cohen has worked at the Mellen MS Center at the Cleveland Clinic since 1994 and was Director 2014-2017.  He is Director of the Experimental Therapeutics Program, the Clinical Neuroimmunology Fellowship, and the MS Academic Coordinating Center.  Dr. Cohen has a large clinical practice devoted primarily to the care of patients with MS and related disorders.  He has over 200 publications concerning immunologic, imaging, and clinical aspects of MS.  He has been involved in various leadership capacities in a large number of clinical trials of potential therapies for MS, translational studies, studies to validate outcome measures, and observational studies.

Cooper Paul

De Stefano Nicola

Department of Medicine, Surgery and Neuroscience, University of Siena, Italy

Nicola De Stefano is Associate Professor of Neurology at the Department of Medicine, Surgery and Neuroscience, University of Siena, Italy.  He is also Head of the NeuroImaging Laboratory in the same Department; Adjunct Professor, Montreal Neurological Institute, McGill University, Canada; and Honorary Visiting Professor, Imperial College London, UK.

Prof. De Stefano graduated with his MD degree from the University of Siena, Italy, and went on to undertake his internship. After successfully completing his residency in neurology, he went on to pursue postgraduate training overseas in Canada before returning to his alma mater where he obtained his PhD.

Prof. De Stefano’s current research interests lie in multiple sclerosis and other neurological diseases involving the brain white matter. In particular, he is a renowned expert on the clinical application of new neuroimaging techniques in brain and muscle of patients with neurological disease.

Prof. De Stefano is a member of several prestigious professional societies and organisations. She ahs co-chaired the MAGNIMS European network between 2009-2016. He has delivered numerous invited lectures worldwide, and to date, he has published numerous books and book chapters as well as more than 300 papers in prestigious international peer-review publications in the area of multiple sclerosis, neurometabolic disorders and neuroimaging.

Edan Gilles

Gilles Edan is currently professor of clinical neurology and chair of the Department of Neurosciences at the University Hospital of Rennes, France. After completing his MD at the University of Rennes in 1981, he went on to specialize in neurology under the supervision of Pr Olivier Sabouraud , was a research fellow at Guy’s hospital (London) in neuroimmunology with RAC Hughes in 1987, spent a sabbatical period of 6 months at the MS clinic of UBC with Don Paty and Joel Oger in Vancouver in 1996 and set up a MS clinic in Brittany in 1996. Gilles Edan was one of the members of the international panel for the new diagnostic criteria of MS (Mc Donald criteria) in 2001 and 2005. He published more than 200 peer-reviewed original papers on his MS researches in Journals and several chapters in books on these subjects.


Feys Peter

Peter Feys (PhD KULeuven, 2004)  is professor in rehabilitation sciences and physiotherapy at Hasselt University, and head of the rehabilitation department within the faculty of medicine and life sciences. He is responsible for education in neurological rehabilitation in a 3 years Bac and 2 years Ma educational program. He is member of inter-university steering committees on rehabilitation sciences and physiotherapy as well as occupational therapy.

His inter-disciplinary research is focused on the assessment and rehabilitation for gait and upper limb function in persons with neurological conditions. It comprises investigations of motor fatigability, music-based entrainment and sonification, upper limb training, cognitive-motor interference, technology-supported training, and community self-directed training. Neuro-imaging is performed to understand the impact of interventions on neural function and structure. The research is performed in persons with Multiple sclerosis and secondary stroke.

Peter Feys has published over 90 peer- reviewed articles in international clinical neurological, imaging, and rehabilitation journals. Funding for research has been obtained from the Flemish research foundation, European Interreg program and charities such as the Flemish MS support fund, Promobilia, RIMS and the Progressive MS Alliance besides university grants.

Peter Feys has been president of RIMS (Rehabilitation in MS;, a European network of best practice and research from 2011-17. He is an editorial board member of ‘Multiple Sclerosis Journal’ and ‘Neurorehabilitation and Neural Repair’.  He has served as management committee member in the COST action TD1006 (European  Network on Robotics for NeuroRehabilitation, 2011-15). In addition, he is secretary of ‘Move to Sport’ ( and member of the Flemish MS Support fund. Previously, Peter Feys was member of the Italian MS Society review board.

Hobart Jeremy

Dr. Jeremy Hobart is a Consultant Neurologist at Derriford Hospital, and Professor at the Plymouth University Peninsula Schools of Medicine and Dentistry. His clinical sub-specialist interest is the diagnosis and management of people with multiple sclerosis. His medical training was at St Mary’s Hospital Medical School in London, and neurology training was undertaken predominantly at the National Hospital for Neurology and Neurosurgery, Queen Square. He is also President of the South Devon branch of the MS Society.

Jeremy Hobart’s research interest is rating scales for measuring health outcomes. His training in health measurement and rating scale science has included a PhD in Psychometrics from the London School of Hygiene and Tropical Medicine (Prof Donna Lamping), and post doctoral attachments to the University of Chicago (Prof Ben Wright) and, more recently, a secondment to Murdoch University Perth, Western Australia (Prof David Andrich) sponsored by a Royal Society of Medicine Ellison-Cliffe Travelling Fellowship. By a combination of chance and design, this training means that Jeremy is one of only a handful of clinicians formally trained in rating scale science. He has led the development of a number of rating scales, has published widely in this area, and holds over £7 million in research grants.Jeremy Hobart is a Consultant Neurologist at Plymouth Hospitals NHS Trust, and Professor in Clinical Neurology and Health Measurement at the Plymouth University Peninsula Schools of Medicine and Dentistry.

Kalincik Tomas

Associate professor Tomas Kalincik is a consultant neurologist at the Royal Melbourne Hospital and principal research fellow at the University of Melbourne. He is the head of the Clinical Outcomes Research (CORe) Unit, which specialises in research of observational data in neurology.

Tomas trained as a neurologist in the Czech Republic and he holds a degree in medicine/surgery from Charles University in Prague, PhD in neuroscience from the University of New South Wales and a Postgraduate Certificate of Biostatistics from the University of Melbourne.

Tomas is a member of the MSBase Scientific Leadership Group and the chair of the MSBase Data Quality Committee. Together with the CORe Unit, he is an active participant in the global MSBase collaboration. He has led a number of MSBase publications and collaborative research projects within as well as outside the MSBase network. His main research interests span treatment outcomes in MS, individualised therapy, prognostics, epidemiology and utility of volumetric MRI in MS.

Kuhle Jens

Leocani Letizia

Letizia Leocani is Associate Professor of Neurology at San Raffaele University and Supervisor of the Experimental Neurophysiology Unit and of Magnetic IntraCerebral Stimulation center. She had a PhD in Human Physiology and she has been Research Fellow at the Human Motor Control Section of the National Institutes of Health in Bethesda-USA. She is Co-Chair of the Clinical Neurophysiology scientific panel of the European Academy of Neurology. Her fields of interest involve translational validation of electrophysiological and OCT markers of neurological diseases and of treatment using non invasive brain stimulation.

Conflict of Interest form

Lebrun Frenay Christine

Dr Christine Lebrun Frenay, MD PhD, is a Neurologist and Oncologist. She is head in inflammatory neurological disorders clinical research unit and MS
center in the university Nice (South East of France) hospital and Senior Professor at UTSW (Dallas, TX). She is member of French Neurological
Society, French MS Society, which she was president and of European and American academies of Neurology. In 2008 she described the first cohort of
a subclinical form of MS and subsequently co-founded with American, European and Turkish colleagues the RIS Consortium which expanded
worldwide to collect a unique extensive patients cohort. Her particular research interest includes therapeutical and MRI studies in MS with a
specific implication in the description of Radiologically Isolated Syndrome (RIS). She is participating in numerous clinical trials and research studies
with international publications in neuro inflammatory diseases. She is a member of several editorial boards of scientific journals, scientific boards
and involved in medical evaluations for MS patients’ associations.

Lycke Jan

Jan Lycke obtained his MD at the faculty of medicine at Gothenburg University 1983 and a PhD from the Institute of Neuroscience and Physiology at the same faculty1993. He became a board certified specialist in Clinical Neurology 1989. Since 2014 Jan Lycke is professor of neurology at the Sahlgrenska Academy, Gothenburg and is currently head of MS research at the MS Centre at Sahlgrenska University Hospital, Gothenburg, Sweden. He has previously been Director of the Department of Neurology at Sahlgrenska University Hospital 1999-2001, President of the Swedish MS Association 2003-2005, and President of the Swedish Neurological Society 2004-2006. He was a Swedish delegate of the council of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2006-2010 and chaired the ECTRIMS/RIMS meeting 2010 in Gothenburg. He is currently a member of the scientific panel of multiple sclerosis of EAN, the steering committee of the Swedish MS Registry, chairman of the board of MS therapies, Swedish MS Association, and Director of the Foundation for MS research in Sweden. He has been the principle investigator on numerous clinical treatment trials in MS. He has published scientific papers in epidemiology, virology and immunology of MS and is currently working with projects of biological markers for characterising the immunpathogenesis of MS, monitoring disease activity and therapeutic interventions of MS.

Marrie Ruth Ann 

Professor, Department of Internal Medicine (Neurology), University of Manitoba.

Professor, Department of Community Health Sciences, University of Manitoba

Director, Multiple Sclerosis Clinic

Degrees/Fellowship: MD, PhD, FRCPC


Montalban Xavier

Professor Xavier Montalban is Chairman of the Department of Neurology-Neuroimmunology and Director of the Multiple
Sclerosis Centre of Catalonia at the Vall d’Hebron University Hospital in Barcelona, where he is former director of the
Department of Neuroscience, and is also the chief of the Neuroimmunology Research Group at the Vall d’Hebron Research
Institute. He is Professor of Neurology at the Universitat Autònoma de Barcelona. Dr. Montalban received his medical license, trained
as a Neurology specialist and completed his PhD in Neuroimmunology during the 1980s at the Universitat Autònoma
de Barcelona. He went on to undertake a postdoctoral fellowship at the Lupus Research Institute, Guy’s & St.Thomas’ Hospital plus
additional clinical training at the National Hospital for Neurology and Neurosurgery, Queen Square in London, United Kingdom

More information

Peeters Liesbet

Liesbet Peeters’ mission as a researcher is to not only do great research, but to make sure that great research practices become widely accessible. Her dream is that one day research data will have maximal impact and that researchers think and communicate without restrictions. Therefore, she is investigating safe and efficient ways to share publicly funded data. She is a postdoctoral researcher at BIOMED, Uhasselt in the lab of prof. Niels Hellings and the project manager of the research project “MS DataConnect” ( The ultimate goal of MS DATACONNECT is for data to achieve maximal impact. We aim to transform the mostly population based management of Multiple Sclerosis (MS) of today into an individualized, personalized and precision level management. We believe the key to achieve this next level of MS management is “F.A.I.R.” data. F.A.I.R. stand for Findable, Accessible, Interoperable and Re-usable. Currently, data is used rather superficially whereas we assume many new insight are to be discovered using the data that is already there. However, two main hurdles obstruct us from reaching these insights. First, most data is not findable, not accessible, not interoperable and not re-usable. Secondly, we lack proper analytical tools for optimal data mining. With this project, we aim to overcome these two obstructions. The MS DataConnect consortium is setting up a Belgian national multidisciplinary repository in colllaboration with

Rae-Grant Alex, MD, FRCP(C)

Dr. Rae-Grant serves as director of education for the Mellen Center for MS and is a past Medical Director for the Cleveland Clinic Center for Continuing Education. He is the neurology editor for DynaMed Plus, a web based point of care tool for clinical medicine. He is a professor of medicine (neurology) at Cleveland Clinic Lerner College of Medicine. He is author of multiple textbooks of neurology and multiple sclerosis. He received his undergraduate degree in biochemistry from Yale University and his Medical degree from the McMaster University Medical School. He obtained his neurology residency from the University of Western Ontario. He co-chaired an American academy of neurology panel developing quality measures for multiple sclerosis and serves on the National Quality Forum Neurology Standing Committee as well as the American Academy of Neurology Guideline Development Dissemination and Implementation Committee. He runs multiple live courses in neurology and multiple sclerosis for the Cleveland Clinic.

Schippling sven

Sven Schippling is head of the Neuro-OCT Reading Centre Zurich. He is a neurologist by training with a strong interest in clinical neuroimmunology, mainly Multiple Sclerosis (MS).  In recent years, he has been focusing on multimodal imaging approaches including structural MRI, optical coherence tomography (OCT), and systems electrophysiology (transcranial magnetic stimulation [TMS]). He is the Co-Director of the Clinical Research Priority Program Multiple Sclerosis (CRPPMS) funded by the University of Zurich and senior clinician at the Department of Neurology of the University Hospital Zurich.

Sormani Mariapia

Maria Pia Sormani, PhD is Professor of Biostatistics at the University of Genoa, Italy, where she teaches biostatistics and research methods to medical students.

Dr. Sormani has collaborated for more than ten years with the Neuroimaging Research Unit at the San Raffaele Hospital in Milan, studying the methodological issues related to the use of Magnetic Resonance Imaging in Multiple Sclerosis. She was also a fellow at the Unit of Clinical Epidemiology and at the Biophysics Unit for the National Institute for Cancer Research in Genoa in cancer clinical studies for over twelve years. She serves on the US Multiple Sclerosis National Society Clinical Trials Advisory Committee.

Dr. Sormani has published more than 200 papers in peer reviewed journals. She received her Master in Medical Biostatistics at the University of Milan, her Master in Medical Physics at the University of Pisa, and her degrees in Physics at the University of Genoa in Italy.

Teunissen Charlotte


Charlotte Teunissens research mission is to cure dementia disorders through development of body fluid biomarkers. The studies of her research group cover the entire spectrum of biomarker development. The studies start with biomarker identification, hypothesis based as well as by proteomics methods, including mass spectrometry and array-based proteomics technologies. The group puts strong effort in analytical and clinical validation for diagnostic use of the most promising biomarkers by immunoassays. The lab is experienced in state of the art technologies, such as Quanterix ultrasensitive Simoa technology, Mesoscale technology and in vitro diagnostic technologies for clinical routine lab analysis. These studies are all based on the availability of a well-characterised biobanks of >5000 paired CSF and serum samples of dementia patients (a.o. Alzheimer, Frontotemporal, Lewy Bodies) as well as Multiple Sclerosis patients (n=200) that visit the outpatient clinics of the VU University Medical Center Amsterdam. To ensure the quality of biosamples, Teunissen performs scientific studies to detect e.g. sentinel biomarkers, and take the lead in guideline development for CSF biomarker study methodology. Teunissen has always collaborated strongly in the field, as this is a prerequisite for performing high quality biomarker studies, visible in her lead in the BioMS network, the Society for Neurochemistry and routine CSF analysis, and the Alzheimer Association-global biomarker standardization consortium.

Vermersch Patrick

MD – Neurology
Professor of Neurology University of Lille
Clinique neurologique, service de neurologie D et pathologie neuro-inflammatoire
CHU Lille